Skip to main content
. 2021 Jan 5;5(1):185–197. doi: 10.1182/bloodadvances.2020001665

Figure 2.

Figure 2.

BCR signaling and cell adhesion transcriptional programs are inhibited in a coordinated fashion by ibrutinib in drug-sensitive cells but not drug-resistant cells. (A) Left: heatmap representing changes in the BCR gene signature cataloged in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. JeKo-1 vs MAVER-1. JeKo-1 and MAVER-1 cells were treated with DMSO or ibrutinib 400 nM for 16 hours. Biological triplicate experiments, represented by 3 columns for each condition, were conducted and shown. A few representative genes are indicated with arrows. Right: enrichment plot of the BCR gene signature analyzed by using Gene Set Enrichment Analysis. P values and FDR are indicated. (B) Left: heatmap representing changes in the CAM gene signature, JeKo-1 vs MAVER-1. Biological triplicate experiments, represented by 3 columns for each condition, were conducted and shown. A few representative genes are indicated with arrows. Right: enrichment plot of the CAM gene signature analyzed using Gene Set Enrichment Analysis. P values and FDR are indicated.